United States Influenza Vaccines Market Analysis Report 2023: COVID-19/Influenza Combination Vaccines Gaining Momentum with GSK, CureVac and Novavax's Continued Advancements

Rhea-AI Summary

The U.S. influenza vaccines market was valued at US$ 3,962 million in 2022 and is projected to reach US$ 8,347 million by 2031, witnessing a CAGR of 8.6%. This growth is driven by increasing R&D, the launch of quadrivalent vaccines, an aging population, and heightened vaccine awareness. The U.S. remains the largest influenza vaccines market globally. Key market participants include BiondVax Pharmaceuticals (BVXV), Novavax, and GSK, among others. The report provides insights into market dynamics, vaccination trends, pricing analysis, and regulatory frameworks from 2018 to 2031. Additionally, the ongoing COVID-19 pandemic is expected to further drive demand for influenza vaccines.

Positive

• U.S. influenza vaccines market expected to grow from $3.96 billion in 2022 to $8.34 billion by 2031.
• CAGR of 8.6% forecasted for the market.
• Increased demand due to COVID-19 pandemic.
• Emerging vaccine candidates from companies such as Moderna and Novavax.

Negative

• None.

DUBLIN, April 20, 2023 /PRNewswire/ -- The "United States Influenza Vaccines Market Size, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2031" report has been added to  ResearchAndMarkets.com's offering.

The influenza vaccines market in the United States was valued at US$ 3,962 million in 2022 and is expected to reach US$ 8,347 million by 2031, registering a CAGR of 8.6% during the forecast period.

This report on the influenza vaccines market in the United States is a comprehensive study and presentation of drivers, restraints, opportunities, demand, market size, forecasts, and trends in the influenza vaccines market in the United States during 2018-2031. In addition, the report is a collective presentation of primary and secondary research findings.

Rapid market expansion is primarily due to increased research & development, the introduction of quadrivalent influenza vaccines, the aging population, and vaccine awareness. In addition, expanded recommendations from government and advisory bodies to get influenza vaccines are driving market growth in the United States.

Influenza is the second leading cause of death from vaccine-preventable disease in the United States after COVID-19. Rates of seasonal influenza infection are highest in children, but the risks for complications, hospitalizations, and deaths are higher in adults 65 years of age and older, children younger than 5 years, pregnant women, and people of any age with conditions that place them at increased risk for influenza complications.

The Most Important Questions are Answered in this 2023 Report:

• What is the current size of the U.S. influenza vaccine market?
• What will be the CAGR of the influenza vaccine market in the United States?
• How many people will be vaccinated with flu vaccines in the U.S. between 2018 and 2031?
• What percentage of people in the United States get vaccinated against influenza?
• What are the main flu vaccines available in the United States?
• What are the key drivers of the influenza vaccine market in the United States?
• What are the major barriers to the influenza vaccine market in the United States?
• What is the reimbursement pattern in the influenza vaccine market in the United States?
• What is the regulatory framework for the influenza vaccine market in the United States?
• What are the key deals and agreements in the United States influenza vaccine market?
• What are the upcoming flu vaccines that will significantly impact the market in the future?
• Who are the main market participants? What is happening with them, what revenues do they generate from vaccines, and what are the current developments and scenarios?
• Who are the new players? What are their events, clinical developments, platform technologies, phases, and current developments?
• How is the market likely to develop in the future?

Key Market Developments

• The United States continues to be the world's largest influenza vaccines market
• Demand for influenza vaccines is expected to increase over the forecast period due to the pandemic COVID -19
• Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, A Seasonal Influenza Vaccine Candidate
• Novavax announces initiation of Phase 2 study for COVID-19 influenza combination vaccine and stand-alone influenza vaccine candidate
• GSK and CureVac advance mRNA COVID-19 and influenza vaccine candidates
• Seqirus receives a government contract to develop 2 influenza vaccines

Company Profiles

• Sanofi Pasteur
• GlaxoSmithKline (GSK)
• Seqirus
• AstraZeneca

Emerging Company Profiles

• Novavax
• BiondVax Pharmaceuticals Ltd.
• Medicago
• Moderna Inc.
• Pneumagen
• Altimmune
• Daiichi Sankyo
• FluGen
• Imutex
• EpiVax
• Versatope Therapeutics, Inc.

Key Attributes:

Report Attribute	Details
No. of Pages	220
Forecast Period	2022 - 2031
Estimated Market Value (USD) in 2022	$3.96 Billion
Forecasted Market Value (USD) by 2031	$8.34 Billion
Compound Annual Growth Rate	8.6 %
Regions Covered	United States

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. United States Influenza Vaccines Market Size, Insights, Analysis, and Forecasts (2018-2031)

5. United States Number of Persons Vaccinated with Influenza Vaccines (2018-2031)

6. Key Market Growth Drivers and Challenges of the United States Influenza Vaccines Market

7. United States Influenza Vaccines Pricing Analysis, Trends and Insights

8. United States Influenza Vaccines Production, Supply, and Allocation (By Companies), 2014-2022

9. United States Influenza Vaccines Distribution and Demand Analysis 2010-2022

10. Effectiveness of Influenza Vaccines in the United States, 2004-2022

11. Rapid Diagnostic Testing for the Management of Influenza

12. Distribution Channel and Technique Detailed Insights of Influenza Vaccination in the United States

13. Reimbursement Environment of the United States Influenza Vaccines Market

14. Regulatory Framework of the United States Influenza Vaccines Market

15. Major Deals and Agreement Activities in the Influenza Vaccines Market

16. Promising Influenza Vaccines in the Clinical Development

17. Influenza Vaccines Clinical Trial Insights by Phase, Company and Country

For more information about this report visit https://www.researchandmarkets.com/r/wojh5p

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/united-states-influenza-vaccines-market-analysis-report-2023-covid-19influenza-combination-vaccines-gaining-momentum-with-gsk-curevac-and-novavaxs-continued-advancements-301802812.html

SOURCE Research and Markets

FAQ

What is the current market value of influenza vaccines in the U.S.?

The current market value is approximately US$ 3,962 million as of 2022.

What is the projected market value of U.S. influenza vaccines by 2031?

The projected market value is US$ 8,347 million by 2031.

What is the expected CAGR for the U.S. influenza vaccines market?

The expected CAGR is 8.6% from 2022 to 2031.

Who are the key market participants in the U.S. influenza vaccine sector?

Key participants include BiondVax Pharmaceuticals, Novavax, and GlaxoSmithKline.

What factors are driving the growth of the influenza vaccines market?

Growth drivers include increased R&D, quadrivalent vaccine introduction, an aging population, and heightened vaccine awareness.